NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $1.40 +0.06 (+4.48%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.42 +0.02 (+1.07%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About SELLAS Life Sciences Group Stock (NASDAQ:SLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SLS alerts:Sign Up Key Stats Today's Range$1.36▼$1.4750-Day Range$1.04▼$1.4052-Week Range$0.77▼$1.84Volume2.44 million shsAverage Volume1.37 million shsMarket Capitalization$127.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Read More… SELLAS Life Sciences Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreSLS MarketRank™: SELLAS Life Sciences Group scored higher than 15% of companies evaluated by MarketBeat, and ranked 901st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for SELLAS Life Sciences Group. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.57) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about SELLAS Life Sciences Group's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.17% of the float of SELLAS Life Sciences Group has been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently decreased by 5.01%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.17% of the float of SELLAS Life Sciences Group has been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently decreased by 5.01%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.14 News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for SELLAS Life Sciences Group this week, compared to 1 article on an average week.Search Interest1 people have searched for SLS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Stock News HeadlinesSELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comSellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trialApril 9, 2025 | markets.businessinsider.comOne daily setup = a shot at a payout by 4PMNo good news has hit the headlines since the last days of February. It's been from one chaos to the next – and of course the market has suffered a heavy blow. Since its peak in February, the S&P 500 has lost around 11 trillion dollars in value and has been struggling to recover. And when we thought things couldn't get any worse, the market hit its first Death Cross (Wall Street's most dreaded bearish indicator) in 3 years. But, while all these happened, a small group of traders have been taking the market to the cleaners. Regular folks have been leveraging a hidden anomaly that has the power to pay out at the 4PM close.April 27, 2025 | WealthPress (Ad)SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AMLApril 8, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common Stock (SLS) Insider ActivityMarch 30, 2025 | nasdaq.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deSELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 20, 2025 | globenewswire.comSellas reports Phase IIa trial data of SLS009 for DLBCL treatmentFebruary 21, 2025 | msn.comSee More Headlines SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $1.04 at the beginning of 2025. Since then, SLS shares have increased by 34.6% and is now trading at $1.40. View the best growth stocks for 2025 here. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) released its quarterly earnings results on Thursday, March, 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. When did SELLAS Life Sciences Group's stock split? Shares of SELLAS Life Sciences Group reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SELLAS Life Sciences Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include (UNISQ) (UNISQ), Amgen (AMGN), Generex Biotechnology (GNBT), Salesforce (CRM), Bank of America (BAC), Bristol-Myers Squibb (BMY) and AbbVie (ABBV). Company Calendar Last Earnings3/20/2025Today4/27/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLS CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-629.46% Return on Assets-178.65% Debt Debt-to-Equity RatioN/A Current Ratio2.26 Quick Ratio2.26 Sales & Book Value Annual Sales$1 million Price / Sales127.19 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-5.60Miscellaneous Outstanding Shares90,847,000Free Float69,537,000Market Cap$127.19 million OptionableNot Optionable Beta2.53 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:SLS) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.